证券日报网讯8月4日晚间，嘉应制药（002198）发布公告称，截至2025年7月31日，公司通过股票回购 专用证券账户以集中竞价方式已累计回购公司股份9，240，000股，占公司目前总股本的1.8206%。 ...

（文章来源：每日经济新闻） 嘉应制药（SZ 002198，收盘价：6.94元）8月4日晚间发布公告称，截至2025年7月31日，公司通过股票 回购专用证券账户以集中竞价方式已累计回购公司股份924万股，占公司目前总股本的1.8206%，回购 的最高成交价格为7.04元/股，最低成交价格为5.96元/股，成交总金额约为6226万元。 2024年1至12月份，嘉应制药的营业收入构成为：医药行业占比99.8%，其他业务占比0.2%。 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-043 广东嘉应制药股份有限公司 关于股份回购进展情况的公告 2025年1月3日，公司首次实施了股份回购。根据《深圳证券交易所上市公司 自律监管指引第9号——回购股份》等相关规定，公司在回购期间应当在每个月 的前三个交易日内披露截至上月末的回购进展情况。现将公司截至上月末的回购 进展情况公告如下： 二、股份回购进展情况 截至2025年7月31日，公司通过股票回购专用证券账户以集中竞价方式已累 计回购公司股份9,240,000股，占公司目前总股本的1.8206%，回购的最高成交价 格为7.04元/股，最低成交价格为5.96元/股，成交总金额为62,258,006元（不含交 易费用）。 本次回购股份资金来源为公司自有资金，回购价格未超过回购方案中拟定的 价格上限9.80元/股。本次回购符合相关法律法规及公司既定回购股份方案的要求。 三、其他事项说明 公司将在回购期限内根据市场情况择机作出回购决策并予以实施，同时将根 据回购事项进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 本公司及董事会保证本公告内容的真实、准确和完整，不存在 ...

Core Viewpoint - Jia Ying Pharmaceutical is facing administrative penalties from the China Securities Regulatory Commission for violations related to information disclosure and improper related-party transactions [3][4] Group 1: Regulatory Actions - The company and its key personnel, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice of administrative penalties for failing to disclose related-party transactions properly [3][4] - The Guangdong Regulatory Bureau plans to impose a fine of 1.5 million yuan on Jia Ying Pharmaceutical and varying fines on the individuals involved, with Li Neng facing a fine of 160,000 yuan [4] Group 2: Related-Party Transactions - Between October 2024 and January 2025, Jia Ying Pharmaceutical's subsidiary provided short-term loans to its related party, Hunan Yao Juneng, totaling 220 million yuan, which accounted for 28.83% of the company's audited net assets at that time [3] - The transactions were not conducted in accordance with the required approval procedures and were not disclosed in a timely manner [3] Group 3: Company Background - Jia Ying Pharmaceutical, established in 2003 and listed on the Shenzhen Stock Exchange in 2007, specializes in the research, production, and sales of traditional Chinese medicine [6] - The company has total assets exceeding 1 billion yuan and a market capitalization of nearly 3 billion yuan [6] Group 4: Financial Performance - In 2024, Jia Ying Pharmaceutical reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit of 20.61 million yuan, down 39.94% [7] - In the first quarter of 2025, the company saw a revenue increase of 28.83% year-on-year, reaching 122 million yuan, and a net profit increase of 197.23%, totaling 15.40 million yuan [7]

Core Viewpoint - On August 1, 2023, Jiaying Pharmaceutical (002198) received an administrative penalty notice from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for failing to timely disclose 220 million yuan in related party fund borrowing, resulting in fines for the company and its responsible persons [1][2]. Group 1: Administrative Penalties - Jiaying Pharmaceutical was fined 1.5 million yuan, while its chairman Li Neng was fined 160,000 yuan, general manager You Yongping 100,000 yuan, and former financial director Shi Junping 80,000 yuan, totaling 4.9 million yuan [1][2]. - The violations involved non-operating fund transactions that were not disclosed until the 2024 annual report, constituting a breach of the Securities Law [2]. Group 2: Company Background - Jiaying Pharmaceutical is a traditional Chinese medicine manufacturer established in 2003, with R&D, production, and sales bases in Changsha, Hunan Province, and Meizhou, Guangdong Province [3][4]. - As of August 4, 2025, the company's total market value was 3.517 billion yuan, with a product portfolio that includes 70 approved drug varieties across various therapeutic areas [4].

Group 1 - The core viewpoint of the articles highlights that under the backdrop of increasing health demands from residents, traditional Chinese medicine companies are expanding their development space through innovative research and development [1][2] - Recently, Jia Ying Pharmaceutical signed research and development cooperation agreements with several institutions, aiming to deepen involvement in multiple innovative and generic drug projects [1] - The cooperation includes the technology transfer of the chemical drug Bilastine tablets and the joint development of high-end generic drug projects JH003 and JH004, targeting areas such as hyperuricemia/gout and heart failure [1] Group 2 - This collaboration is a significant implementation of Jia Ying Pharmaceutical's "4+4" strategy, focusing on new drug research and new product introduction as core strategic elements [2] - The company aims to build a product matrix that integrates traditional Chinese medicine innovation with the field of chemical drug generics, leveraging its "Keya" brand advantages in traditional Chinese medicine [2] - Future plans include enhancing the penetration of core categories in hospitals, OTC, and new retail channels, transitioning the "Keya" brand from product output to health solution provision [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 按照相关法律法规的规定，上市公司证券虚假陈述，给投资人造成的投资损失，应当负赔偿责任。 陈宇霞律师在此提醒，凡在2024年10月01日至2025年04月25日之间买入嘉应制药，且在2025年04月26日 之后继续持有或卖出亏损的投资者，均有权向嘉应制药索赔相关投资损失。以上索赔条件仅代表陈宇霞 律师的观点，不作为任何投资决策和买卖建议，最终以法院认定的索赔条件为准。 参加股票索赔的股民需准备一下材料； 1、股票交易对账单（如对账单上未显示完整的身份证号码，需另外打印股东信息表；对账期间从第一 次买入至完全卖出（或打印对账单之日） 2025年08月4日，广东嘉应制药（维权）股份有限公司发布《关于公司及相关责任人收到<行政处罚事 先告知书>的公告》。因嘉应制药涉嫌信息披露违法违规，广东证监局拟决定对其给予行政处罚。 违法事实 广东证监局经调查认定，嘉应制药存在如下违法事实： 嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称药聚能）的实际控制人，药聚能构成嘉应制 药的关联方。2024年10月至 2025年1月期间，因药聚能存在短期资金需求，嘉应制药的子公司嘉应制 ...

Group 1 - The core issue involves Guangdong Jiaying Pharmaceutical Co., Ltd. facing administrative penalties from the China Securities Regulatory Commission for failing to disclose related party transactions [1] - The company’s subsidiary, Hunan Jiaying, provided short-term loans to a related party, Hunan Yaojuneng Pharmaceutical Co., Ltd., controlled by the chairman, amounting to 219.99 million yuan, which is 28.83% of the company's latest audited net assets [1] - The related party transactions were not properly reviewed or disclosed until the 2024 annual report, violating relevant securities laws [1] Group 2 - The Guangdong Securities Regulatory Bureau plans to impose a warning and a fine of 1.5 million yuan on Jiaying Pharmaceutical [1] - Chairman Li Neng is to receive a warning and a fine of 1.6 million yuan, while other executives, including General Manager You Yongping and former CFO Shi Junping, will also face fines [1]

000558 天府文旅 B004 000826 启迪环境 B001 000998 隆平高科 B001 001236 弘业期货 A07 001314 亿道信息 A06 001324 长青科技 A06 002037 保利联合 A06 002198 嘉应制药 A07 002219 新里程 B001 002330 得利斯 B007 002408 齐翔腾达 B003 002424 贵州百灵 A07 002600 领益智造 B007 002629 仁智股份 A07 002634 棒杰股份 A07 002716 湖南白银 A06 002775 文科股份 B004 002799 环球印务 A07 002921 联诚精密 A07 002940 昂利康 B004 002951 金时科技 A06 300691 联合光电 A06 301632 广东建科 A08 600009 上海机场 A08 600031 三一重工 A08 600104 上汽集团 A08 600166 福田汽车 B003 600507 方大特钢 B001 平安基金 B003 融通基金 B007 上银基金 B005 天弘基金 B006 太平基金 B005 信达证券基金 ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Group 1: Investigation and Allegations - The company received a notice of investigation from the CSRC on May 28, 2025, due to suspected violations of information disclosure laws [1]. - The investigation revealed that the company's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party to Jiaying Pharmaceutical [2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party without following the required disclosure procedures, totaling 21.999 million yuan, which accounted for 28.83% of the company's latest audited net assets [2]. Group 2: Administrative Penalties - The CSRC plans to impose administrative penalties, including a warning and a fine of 1.5 million yuan on Jiaying Pharmaceutical, 1.6 million yuan on Li Neng, 1 million yuan on You Yongping, and 800,000 yuan on Shi Junping [3][4]. - The violations were characterized by a short duration and the company’s timely recovery of non-operating funds, which were disclosed in the 2024 annual report [3]. Group 3: Company Response and Impact - The company believes that the penalties will not lead to significant operational impacts and that it does not fall under the major violations that could trigger mandatory delisting [5]. - Jiaying Pharmaceutical has expressed sincere apologies to investors and committed to enhancing compliance awareness and operational standards [5].